nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—breast cancer	0.102	0.343	CbGaD
Dapagliflozin—CYP2D6—breast cancer	0.0759	0.255	CbGaD
Dapagliflozin—CYP3A4—breast cancer	0.0651	0.219	CbGaD
Dapagliflozin—ABCB1—breast cancer	0.0542	0.182	CbGaD
Dapagliflozin—CYP2A6—Letrozole—breast cancer	0.0488	0.115	CbGbCtD
Dapagliflozin—CYP1A1—Toremifene—breast cancer	0.034	0.0803	CbGbCtD
Dapagliflozin—UGT1A9—Irinotecan—breast cancer	0.023	0.0542	CbGbCtD
Dapagliflozin—UGT2B7—Epirubicin—breast cancer	0.0224	0.0527	CbGbCtD
Dapagliflozin—CYP1A2—Anastrozole—breast cancer	0.0166	0.0392	CbGbCtD
Dapagliflozin—CYP1A2—Toremifene—breast cancer	0.0152	0.0359	CbGbCtD
Dapagliflozin—CYP2C9—Anastrozole—breast cancer	0.015	0.0353	CbGbCtD
Dapagliflozin—CYP2A6—Tamoxifen—breast cancer	0.0145	0.0343	CbGbCtD
Dapagliflozin—ABCB1—Toremifene—breast cancer	0.0133	0.0314	CbGbCtD
Dapagliflozin—CYP1A1—Tamoxifen—breast cancer	0.0124	0.0293	CbGbCtD
Dapagliflozin—CYP3A4—Exemestane—breast cancer	0.0115	0.0271	CbGbCtD
Dapagliflozin—CYP2C9—Idarubicin—breast cancer	0.0113	0.0268	CbGbCtD
Dapagliflozin—CYP2A6—Fluorouracil—breast cancer	0.0107	0.0253	CbGbCtD
Dapagliflozin—CYP2D6—Idarubicin—breast cancer	0.0104	0.0245	CbGbCtD
Dapagliflozin—CYP3A4—Letrozole—breast cancer	0.00977	0.023	CbGbCtD
Dapagliflozin—ABCB1—Lapatinib—breast cancer	0.00969	0.0229	CbGbCtD
Dapagliflozin—CYP3A4—Anastrozole—breast cancer	0.00871	0.0205	CbGbCtD
Dapagliflozin—CYP3A4—Toremifene—breast cancer	0.00796	0.0188	CbGbCtD
Dapagliflozin—CYP3A4—Fulvestrant—breast cancer	0.0074	0.0175	CbGbCtD
Dapagliflozin—CYP3A4—Thiotepa—breast cancer	0.0066	0.0156	CbGbCtD
Dapagliflozin—CYP2C9—Capecitabine—breast cancer	0.00622	0.0147	CbGbCtD
Dapagliflozin—CYP3A4—Ixabepilone—breast cancer	0.00603	0.0142	CbGbCtD
Dapagliflozin—CYP3A4—Lapatinib—breast cancer	0.00581	0.0137	CbGbCtD
Dapagliflozin—CYP1A2—Tamoxifen—breast cancer	0.00555	0.0131	CbGbCtD
Dapagliflozin—ABCB1—Vinorelbine—breast cancer	0.00538	0.0127	CbGbCtD
Dapagliflozin—CYP2D6—Vinorelbine—breast cancer	0.00507	0.012	CbGbCtD
Dapagliflozin—CYP2C9—Tamoxifen—breast cancer	0.005	0.0118	CbGbCtD
Dapagliflozin—ABCB1—Tamoxifen—breast cancer	0.00485	0.0115	CbGbCtD
Dapagliflozin—ABCB1—Mitoxantrone—breast cancer	0.00473	0.0112	CbGbCtD
Dapagliflozin—CYP2D6—Tamoxifen—breast cancer	0.00457	0.0108	CbGbCtD
Dapagliflozin—CYP3A4—Raloxifene—breast cancer	0.0044	0.0104	CbGbCtD
Dapagliflozin—ABCB1—Gemcitabine—breast cancer	0.00418	0.00987	CbGbCtD
Dapagliflozin—CYP1A2—Fluorouracil—breast cancer	0.00409	0.00965	CbGbCtD
Dapagliflozin—CYP2C9—Paclitaxel—breast cancer	0.00389	0.00919	CbGbCtD
Dapagliflozin—ABCB1—Paclitaxel—breast cancer	0.00378	0.00892	CbGbCtD
Dapagliflozin—ABCB1—Irinotecan—breast cancer	0.00373	0.0088	CbGbCtD
Dapagliflozin—CYP2C9—Fluorouracil—breast cancer	0.00369	0.0087	CbGbCtD
Dapagliflozin—ABCB1—Vinblastine—breast cancer	0.00331	0.00782	CbGbCtD
Dapagliflozin—CYP3A4—Vinorelbine—breast cancer	0.00322	0.0076	CbGbCtD
Dapagliflozin—CYP2D6—Vinblastine—breast cancer	0.00312	0.00737	CbGbCtD
Dapagliflozin—CYP3A4—Tamoxifen—breast cancer	0.00291	0.00686	CbGbCtD
Dapagliflozin—CYP3A4—Mitoxantrone—breast cancer	0.00284	0.00669	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—breast cancer	0.00273	0.00645	CbGbCtD
Dapagliflozin—SLC5A1—mammary gland—breast cancer	0.00249	0.145	CbGeAlD
Dapagliflozin—CYP3A4—Paclitaxel—breast cancer	0.00226	0.00534	CbGbCtD
Dapagliflozin—CYP3A4—Irinotecan—breast cancer	0.00223	0.00527	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—breast cancer	0.00204	0.00481	CbGbCtD
Dapagliflozin—CYP3A4—Vinblastine—breast cancer	0.00199	0.00469	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—breast cancer	0.00197	0.00465	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—breast cancer	0.00192	0.00453	CbGbCtD
Dapagliflozin—SLC5A11—pituitary gland—breast cancer	0.00178	0.104	CbGeAlD
Dapagliflozin—CYP3A4—Docetaxel—breast cancer	0.00164	0.00386	CbGbCtD
Dapagliflozin—SLC5A1—epithelium—breast cancer	0.00139	0.0808	CbGeAlD
Dapagliflozin—SLC5A1—endometrium—breast cancer	0.00125	0.0725	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—breast cancer	0.00122	0.00288	CbGbCtD
Dapagliflozin—SLC5A2—endocrine gland—breast cancer	0.00115	0.067	CbGeAlD
Dapagliflozin—SLC5A1—pituitary gland—breast cancer	0.00113	0.0656	CbGeAlD
Dapagliflozin—UGT2B4—endocrine gland—breast cancer	0.000805	0.0468	CbGeAlD
Dapagliflozin—Canagliflozin—CYP3A4—breast cancer	0.000723	0.37	CrCbGaD
Dapagliflozin—Canagliflozin—ALB—breast cancer	0.000631	0.323	CrCbGaD
Dapagliflozin—Canagliflozin—ABCB1—breast cancer	0.000602	0.308	CrCbGaD
Dapagliflozin—UGT1A9—endocrine gland—breast cancer	0.00055	0.032	CbGeAlD
Dapagliflozin—UGT2B7—female reproductive system—breast cancer	0.000524	0.0305	CbGeAlD
Dapagliflozin—CYP2C9—mammary gland—breast cancer	0.000452	0.0263	CbGeAlD
Dapagliflozin—UGT2B7—endocrine gland—breast cancer	0.000443	0.0258	CbGeAlD
Dapagliflozin—CYP2A6—adipose tissue—breast cancer	0.000408	0.0237	CbGeAlD
Dapagliflozin—CYP1A2—nipple—breast cancer	0.000394	0.0229	CbGeAlD
Dapagliflozin—CYP1A1—nipple—breast cancer	0.000389	0.0226	CbGeAlD
Dapagliflozin—CYP1A1—epithelium—breast cancer	0.000262	0.0152	CbGeAlD
Dapagliflozin—CYP1A1—skin of body—breast cancer	0.000249	0.0145	CbGeAlD
Dapagliflozin—CYP1A1—uterus—breast cancer	0.000216	0.0126	CbGeAlD
Dapagliflozin—CYP1A1—adipose tissue—breast cancer	0.000212	0.0123	CbGeAlD
Dapagliflozin—CYP1A1—female reproductive system—breast cancer	0.000194	0.0113	CbGeAlD
Dapagliflozin—CYP2C9—female reproductive system—breast cancer	0.000187	0.0109	CbGeAlD
Dapagliflozin—CYP1A1—female gonad—breast cancer	0.000177	0.0103	CbGeAlD
Dapagliflozin—CYP1A2—endocrine gland—breast cancer	0.000167	0.0097	CbGeAlD
Dapagliflozin—ABCB1—embryo—breast cancer	0.000167	0.00969	CbGeAlD
Dapagliflozin—CYP1A1—endocrine gland—breast cancer	0.000165	0.00957	CbGeAlD
Dapagliflozin—CYP2C9—endocrine gland—breast cancer	0.000158	0.00921	CbGeAlD
Dapagliflozin—CYP3A4—female reproductive system—breast cancer	0.000143	0.0083	CbGeAlD
Dapagliflozin—CYP2D6—female reproductive system—breast cancer	0.00014	0.00817	CbGeAlD
Dapagliflozin—ABCB1—epithelium—breast cancer	0.000136	0.00791	CbGeAlD
Dapagliflozin—CYP2D6—female gonad—breast cancer	0.000128	0.00743	CbGeAlD
Dapagliflozin—ABCB1—endometrium—breast cancer	0.000122	0.00709	CbGeAlD
Dapagliflozin—CYP3A4—endocrine gland—breast cancer	0.000121	0.00702	CbGeAlD
Dapagliflozin—CYP2D6—endocrine gland—breast cancer	0.000119	0.00691	CbGeAlD
Dapagliflozin—CYP1A1—lymph node—breast cancer	0.000114	0.00662	CbGeAlD
Dapagliflozin—ABCB1—uterus—breast cancer	0.000112	0.00653	CbGeAlD
Dapagliflozin—ABCB1—pituitary gland—breast cancer	0.00011	0.00642	CbGeAlD
Dapagliflozin—ABCB1—adipose tissue—breast cancer	0.00011	0.00639	CbGeAlD
Dapagliflozin—ABCB1—female reproductive system—breast cancer	0.000101	0.00587	CbGeAlD
Dapagliflozin—ABCB1—adrenal gland—breast cancer	9.85e-05	0.00573	CbGeAlD
Dapagliflozin—ABCB1—bone marrow—breast cancer	9.53e-05	0.00555	CbGeAlD
Dapagliflozin—ABCB1—female gonad—breast cancer	9.19e-05	0.00535	CbGeAlD
Dapagliflozin—ABCB1—endocrine gland—breast cancer	8.55e-05	0.00497	CbGeAlD
Dapagliflozin—Oedema—Gemcitabine—breast cancer	7.18e-05	0.00053	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Gemcitabine—breast cancer	7.18e-05	0.00053	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—breast cancer	7.17e-05	0.000529	CcSEcCtD
Dapagliflozin—Skin disorder—Mitoxantrone—breast cancer	7.16e-05	0.000528	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—breast cancer	7.14e-05	0.000527	CcSEcCtD
Dapagliflozin—Infection—Gemcitabine—breast cancer	7.14e-05	0.000526	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Irinotecan—breast cancer	7.13e-05	0.000526	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mitoxantrone—breast cancer	7.13e-05	0.000526	CcSEcCtD
Dapagliflozin—Back pain—Paclitaxel—breast cancer	7.13e-05	0.000526	CcSEcCtD
Dapagliflozin—Dizziness—Vinblastine—breast cancer	7.12e-05	0.000525	CcSEcCtD
Dapagliflozin—Urticaria—Vinorelbine—breast cancer	7.1e-05	0.000524	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—breast cancer	7.09e-05	0.000523	CcSEcCtD
Dapagliflozin—Body temperature increased—Vinorelbine—breast cancer	7.07e-05	0.000521	CcSEcCtD
Dapagliflozin—Oedema—Fluorouracil—breast cancer	7.06e-05	0.000521	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Fluorouracil—breast cancer	7.06e-05	0.000521	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—breast cancer	7.05e-05	0.00052	CcSEcCtD
Dapagliflozin—Urethral disorder—Docetaxel—breast cancer	7.03e-05	0.000519	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—breast cancer	7.02e-05	0.000518	CcSEcCtD
Dapagliflozin—Infection—Fluorouracil—breast cancer	7.02e-05	0.000518	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—breast cancer	7e-05	0.000516	CcSEcCtD
Dapagliflozin—Skin disorder—Gemcitabine—breast cancer	6.98e-05	0.000515	CcSEcCtD
Dapagliflozin—Nausea—Chlorambucil—breast cancer	6.97e-05	0.000514	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gemcitabine—breast cancer	6.94e-05	0.000512	CcSEcCtD
Dapagliflozin—Dizziness—Tamoxifen—breast cancer	6.91e-05	0.00051	CcSEcCtD
Dapagliflozin—Hypotension—Mitoxantrone—breast cancer	6.89e-05	0.000508	CcSEcCtD
Dapagliflozin—Hypotension—Irinotecan—breast cancer	6.89e-05	0.000508	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Capecitabine—breast cancer	6.86e-05	0.000506	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Capecitabine—breast cancer	6.83e-05	0.000504	CcSEcCtD
Dapagliflozin—Urethral disorder—Capecitabine—breast cancer	6.81e-05	0.000502	CcSEcCtD
Dapagliflozin—Urticaria—Thiotepa—breast cancer	6.78e-05	0.0005	CcSEcCtD
Dapagliflozin—Body temperature increased—Thiotepa—breast cancer	6.75e-05	0.000498	CcSEcCtD
Dapagliflozin—Headache—Vinblastine—breast cancer	6.74e-05	0.000497	CcSEcCtD
Dapagliflozin—Angioedema—Paclitaxel—breast cancer	6.73e-05	0.000497	CcSEcCtD
Dapagliflozin—Hypotension—Gemcitabine—breast cancer	6.71e-05	0.000495	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—breast cancer	6.63e-05	0.000489	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—breast cancer	6.61e-05	0.000487	CcSEcCtD
Dapagliflozin—Dizziness—Goserelin—breast cancer	6.6e-05	0.000487	CcSEcCtD
Dapagliflozin—Hypotension—Fluorouracil—breast cancer	6.6e-05	0.000487	CcSEcCtD
Dapagliflozin—Rash—Tamoxifen—breast cancer	6.59e-05	0.000486	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vinorelbine—breast cancer	6.59e-05	0.000486	CcSEcCtD
Dapagliflozin—Dermatitis—Tamoxifen—breast cancer	6.58e-05	0.000486	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—breast cancer	6.55e-05	0.000483	CcSEcCtD
Dapagliflozin—Headache—Tamoxifen—breast cancer	6.55e-05	0.000483	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—breast cancer	6.51e-05	0.00048	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—breast cancer	6.5e-05	0.000479	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—breast cancer	6.47e-05	0.000478	CcSEcCtD
Dapagliflozin—Rash—Melphalan—breast cancer	6.45e-05	0.000476	CcSEcCtD
Dapagliflozin—Dermatitis—Melphalan—breast cancer	6.45e-05	0.000476	CcSEcCtD
Dapagliflozin—Nausea—Vinblastine—breast cancer	6.39e-05	0.000471	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—breast cancer	6.39e-05	0.000471	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Irinotecan—breast cancer	6.37e-05	0.00047	CcSEcCtD
Dapagliflozin—Hypertension—Paclitaxel—breast cancer	6.36e-05	0.000469	CcSEcCtD
Dapagliflozin—Constipation—Mitoxantrone—breast cancer	6.31e-05	0.000465	CcSEcCtD
Dapagliflozin—Constipation—Irinotecan—breast cancer	6.31e-05	0.000465	CcSEcCtD
Dapagliflozin—Rash—Goserelin—breast cancer	6.3e-05	0.000464	CcSEcCtD
Dapagliflozin—Hypersensitivity—Thiotepa—breast cancer	6.29e-05	0.000464	CcSEcCtD
Dapagliflozin—Dermatitis—Goserelin—breast cancer	6.29e-05	0.000464	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—breast cancer	6.26e-05	0.000461	CcSEcCtD
Dapagliflozin—Headache—Goserelin—breast cancer	6.25e-05	0.000461	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—breast cancer	6.25e-05	0.000461	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	6.23e-05	0.00046	CcSEcCtD
Dapagliflozin—Nausea—Tamoxifen—breast cancer	6.21e-05	0.000458	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gemcitabine—breast cancer	6.2e-05	0.000458	CcSEcCtD
Dapagliflozin—Discomfort—Paclitaxel—breast cancer	6.2e-05	0.000457	CcSEcCtD
Dapagliflozin—Constipation—Gemcitabine—breast cancer	6.14e-05	0.000453	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fluorouracil—breast cancer	6.1e-05	0.00045	CcSEcCtD
Dapagliflozin—Nausea—Melphalan—breast cancer	6.08e-05	0.000448	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—breast cancer	6.06e-05	0.000447	CcSEcCtD
Dapagliflozin—Malnutrition—Capecitabine—breast cancer	6.05e-05	0.000446	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—breast cancer	6.05e-05	0.000446	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—breast cancer	6.04e-05	0.000446	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—breast cancer	6.04e-05	0.000446	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—breast cancer	6.02e-05	0.000444	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Paclitaxel—breast cancer	6.01e-05	0.000444	CcSEcCtD
Dapagliflozin—Oedema—Paclitaxel—breast cancer	6.01e-05	0.000444	CcSEcCtD
Dapagliflozin—Infection—Paclitaxel—breast cancer	5.98e-05	0.000441	CcSEcCtD
Dapagliflozin—Nausea—Goserelin—breast cancer	5.93e-05	0.000437	CcSEcCtD
Dapagliflozin—Dizziness—Vinorelbine—breast cancer	5.91e-05	0.000436	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—breast cancer	5.91e-05	0.000436	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—breast cancer	5.91e-05	0.00344	CbGeAlD
Dapagliflozin—Angina pectoris—Epirubicin—breast cancer	5.89e-05	0.000435	CcSEcCtD
Dapagliflozin—Urticaria—Mitoxantrone—breast cancer	5.86e-05	0.000432	CcSEcCtD
Dapagliflozin—Back pain—Capecitabine—breast cancer	5.85e-05	0.000432	CcSEcCtD
Dapagliflozin—Skin disorder—Paclitaxel—breast cancer	5.84e-05	0.000431	CcSEcCtD
Dapagliflozin—Body temperature increased—Mitoxantrone—breast cancer	5.83e-05	0.00043	CcSEcCtD
Dapagliflozin—Body temperature increased—Irinotecan—breast cancer	5.83e-05	0.00043	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Paclitaxel—breast cancer	5.81e-05	0.000429	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—breast cancer	5.79e-05	0.000427	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—breast cancer	5.76e-05	0.000425	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—breast cancer	5.76e-05	0.000425	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—breast cancer	5.68e-05	0.000419	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—breast cancer	5.66e-05	0.000418	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—breast cancer	5.65e-05	0.000417	CcSEcCtD
Dapagliflozin—Dizziness—Thiotepa—breast cancer	5.65e-05	0.000417	CcSEcCtD
Dapagliflozin—Rash—Vinorelbine—breast cancer	5.64e-05	0.000416	CcSEcCtD
Dapagliflozin—Dermatitis—Vinorelbine—breast cancer	5.63e-05	0.000416	CcSEcCtD
Dapagliflozin—Hypotension—Paclitaxel—breast cancer	5.62e-05	0.000415	CcSEcCtD
Dapagliflozin—Urticaria—Fluorouracil—breast cancer	5.61e-05	0.000414	CcSEcCtD
Dapagliflozin—Headache—Vinorelbine—breast cancer	5.6e-05	0.000413	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—breast cancer	5.59e-05	0.000413	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—breast cancer	5.59e-05	0.000412	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluorouracil—breast cancer	5.58e-05	0.000412	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—breast cancer	5.45e-05	0.000402	CcSEcCtD
Dapagliflozin—Hypersensitivity—Irinotecan—breast cancer	5.43e-05	0.000401	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mitoxantrone—breast cancer	5.43e-05	0.000401	CcSEcCtD
Dapagliflozin—Hypertension—Docetaxel—breast cancer	5.39e-05	0.000398	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—breast cancer	5.39e-05	0.000398	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—breast cancer	5.39e-05	0.000398	CcSEcCtD
Dapagliflozin—Rash—Thiotepa—breast cancer	5.38e-05	0.000397	CcSEcCtD
Dapagliflozin—Dermatitis—Thiotepa—breast cancer	5.38e-05	0.000397	CcSEcCtD
Dapagliflozin—Headache—Thiotepa—breast cancer	5.35e-05	0.000395	CcSEcCtD
Dapagliflozin—Nausea—Vinorelbine—breast cancer	5.31e-05	0.000392	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—breast cancer	5.3e-05	0.000391	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	5.28e-05	0.00039	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—breast cancer	5.24e-05	0.000387	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—breast cancer	5.23e-05	0.000386	CcSEcCtD
Dapagliflozin—Hypertension—Capecitabine—breast cancer	5.22e-05	0.000385	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluorouracil—breast cancer	5.2e-05	0.000384	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Paclitaxel—breast cancer	5.19e-05	0.000383	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—breast cancer	5.17e-05	0.000381	CcSEcCtD
Dapagliflozin—Constipation—Paclitaxel—breast cancer	5.14e-05	0.000379	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	5.11e-05	0.000377	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—breast cancer	5.11e-05	0.000377	CcSEcCtD
Dapagliflozin—Oedema—Docetaxel—breast cancer	5.1e-05	0.000376	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—breast cancer	5.1e-05	0.000376	CcSEcCtD
Dapagliflozin—Discomfort—Capecitabine—breast cancer	5.09e-05	0.000375	CcSEcCtD
Dapagliflozin—Nausea—Thiotepa—breast cancer	5.07e-05	0.000374	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—breast cancer	5.07e-05	0.000374	CcSEcCtD
Dapagliflozin—Infection—Docetaxel—breast cancer	5.06e-05	0.000374	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—breast cancer	4.99e-05	0.000368	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—breast cancer	4.99e-05	0.000368	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—breast cancer	4.95e-05	0.000365	CcSEcCtD
Dapagliflozin—Oedema—Capecitabine—breast cancer	4.94e-05	0.000364	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—breast cancer	4.9e-05	0.000362	CcSEcCtD
Dapagliflozin—Infection—Capecitabine—breast cancer	4.9e-05	0.000362	CcSEcCtD
Dapagliflozin—Dizziness—Irinotecan—breast cancer	4.88e-05	0.00036	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—breast cancer	4.85e-05	0.000358	CcSEcCtD
Dapagliflozin—Skin disorder—Capecitabine—breast cancer	4.79e-05	0.000354	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—breast cancer	4.78e-05	0.000353	CcSEcCtD
Dapagliflozin—Urticaria—Paclitaxel—breast cancer	4.78e-05	0.000352	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Capecitabine—breast cancer	4.77e-05	0.000352	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—breast cancer	4.76e-05	0.000351	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—breast cancer	4.76e-05	0.000351	CcSEcCtD
Dapagliflozin—Body temperature increased—Paclitaxel—breast cancer	4.75e-05	0.000351	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—breast cancer	4.74e-05	0.00035	CcSEcCtD
Dapagliflozin—Dizziness—Fluorouracil—breast cancer	4.67e-05	0.000345	CcSEcCtD
Dapagliflozin—Rash—Irinotecan—breast cancer	4.65e-05	0.000343	CcSEcCtD
Dapagliflozin—Rash—Mitoxantrone—breast cancer	4.65e-05	0.000343	CcSEcCtD
Dapagliflozin—Dermatitis—Irinotecan—breast cancer	4.65e-05	0.000343	CcSEcCtD
Dapagliflozin—Dermatitis—Mitoxantrone—breast cancer	4.65e-05	0.000343	CcSEcCtD
Dapagliflozin—Headache—Irinotecan—breast cancer	4.62e-05	0.000341	CcSEcCtD
Dapagliflozin—Headache—Mitoxantrone—breast cancer	4.62e-05	0.000341	CcSEcCtD
Dapagliflozin—Hypotension—Capecitabine—breast cancer	4.61e-05	0.00034	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—breast cancer	4.53e-05	0.000334	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—breast cancer	4.53e-05	0.000334	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—breast cancer	4.5e-05	0.000332	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—breast cancer	4.5e-05	0.000332	CcSEcCtD
Dapagliflozin—Rash—Fluorouracil—breast cancer	4.45e-05	0.000329	CcSEcCtD
Dapagliflozin—Dermatitis—Fluorouracil—breast cancer	4.45e-05	0.000328	CcSEcCtD
Dapagliflozin—Hypersensitivity—Paclitaxel—breast cancer	4.43e-05	0.000327	CcSEcCtD
Dapagliflozin—Headache—Fluorouracil—breast cancer	4.42e-05	0.000326	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—breast cancer	4.42e-05	0.000326	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—breast cancer	4.4e-05	0.000325	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—breast cancer	4.4e-05	0.000325	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—breast cancer	4.39e-05	0.000324	CcSEcCtD
Dapagliflozin—Nausea—Mitoxantrone—breast cancer	4.38e-05	0.000323	CcSEcCtD
Dapagliflozin—Nausea—Irinotecan—breast cancer	4.38e-05	0.000323	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—breast cancer	4.36e-05	0.000322	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—breast cancer	4.35e-05	0.000321	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—breast cancer	4.27e-05	0.000315	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Capecitabine—breast cancer	4.26e-05	0.000314	CcSEcCtD
Dapagliflozin—Constipation—Capecitabine—breast cancer	4.22e-05	0.000311	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—breast cancer	4.21e-05	0.000311	CcSEcCtD
Dapagliflozin—Nausea—Fluorouracil—breast cancer	4.2e-05	0.000309	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—breast cancer	4.08e-05	0.000301	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—breast cancer	4.03e-05	0.000297	CcSEcCtD
Dapagliflozin—Dizziness—Paclitaxel—breast cancer	3.98e-05	0.000293	CcSEcCtD
Dapagliflozin—Urticaria—Capecitabine—breast cancer	3.92e-05	0.000289	CcSEcCtD
Dapagliflozin—Body temperature increased—Capecitabine—breast cancer	3.9e-05	0.000288	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—breast cancer	3.9e-05	0.000288	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.81e-05	0.000281	CcSEcCtD
Dapagliflozin—Rash—Paclitaxel—breast cancer	3.79e-05	0.00028	CcSEcCtD
Dapagliflozin—Dermatitis—Paclitaxel—breast cancer	3.79e-05	0.000279	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—breast cancer	3.79e-05	0.000279	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—breast cancer	3.77e-05	0.000278	CcSEcCtD
Dapagliflozin—Headache—Paclitaxel—breast cancer	3.77e-05	0.000278	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—breast cancer	3.76e-05	0.000277	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—breast cancer	3.67e-05	0.000271	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—breast cancer	3.65e-05	0.000269	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—breast cancer	3.64e-05	0.000268	CcSEcCtD
Dapagliflozin—Hypersensitivity—Capecitabine—breast cancer	3.64e-05	0.000268	CcSEcCtD
Dapagliflozin—Nausea—Paclitaxel—breast cancer	3.57e-05	0.000264	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—breast cancer	3.57e-05	0.000263	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.56e-05	0.000263	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—breast cancer	3.55e-05	0.000262	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—breast cancer	3.54e-05	0.000261	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—breast cancer	3.44e-05	0.000254	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—breast cancer	3.44e-05	0.000254	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—breast cancer	3.43e-05	0.000253	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—breast cancer	3.42e-05	0.000252	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—breast cancer	3.37e-05	0.000249	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—breast cancer	3.37e-05	0.000248	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—breast cancer	3.34e-05	0.000246	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—breast cancer	3.32e-05	0.000245	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.3e-05	0.000243	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—breast cancer	3.28e-05	0.000242	CcSEcCtD
Dapagliflozin—Dizziness—Capecitabine—breast cancer	3.26e-05	0.000241	CcSEcCtD
Dapagliflozin—Rash—Docetaxel—breast cancer	3.21e-05	0.000237	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—breast cancer	3.21e-05	0.000237	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—breast cancer	3.21e-05	0.000237	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—breast cancer	3.19e-05	0.000236	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—breast cancer	3.18e-05	0.000235	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—breast cancer	3.18e-05	0.000235	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—breast cancer	3.17e-05	0.000234	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—breast cancer	3.16e-05	0.000233	CcSEcCtD
Dapagliflozin—Rash—Capecitabine—breast cancer	3.11e-05	0.00023	CcSEcCtD
Dapagliflozin—Dermatitis—Capecitabine—breast cancer	3.11e-05	0.000229	CcSEcCtD
Dapagliflozin—Headache—Capecitabine—breast cancer	3.09e-05	0.000228	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—breast cancer	3.09e-05	0.000228	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—breast cancer	3.08e-05	0.000227	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—breast cancer	3.03e-05	0.000223	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—breast cancer	2.97e-05	0.000219	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—breast cancer	2.97e-05	0.000219	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—breast cancer	2.94e-05	0.000217	CcSEcCtD
Dapagliflozin—Nausea—Capecitabine—breast cancer	2.93e-05	0.000216	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—breast cancer	2.92e-05	0.000215	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—breast cancer	2.9e-05	0.000214	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—breast cancer	2.75e-05	0.000203	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—breast cancer	2.73e-05	0.000202	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—breast cancer	2.72e-05	0.000201	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—breast cancer	2.72e-05	0.000201	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—breast cancer	2.71e-05	0.0002	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—breast cancer	2.53e-05	0.000187	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—breast cancer	2.53e-05	0.000186	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—breast cancer	2.52e-05	0.000186	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—breast cancer	2.43e-05	0.000179	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—breast cancer	2.34e-05	0.000173	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—breast cancer	2.32e-05	0.000171	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—breast cancer	2.31e-05	0.000171	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—breast cancer	2.3e-05	0.00017	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—breast cancer	2.27e-05	0.000168	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—breast cancer	2.18e-05	0.000161	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—breast cancer	2.17e-05	0.00016	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—breast cancer	2.17e-05	0.00016	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—breast cancer	2.15e-05	0.000159	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—breast cancer	2.1e-05	0.000155	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—breast cancer	2.04e-05	0.000151	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—breast cancer	2.01e-05	0.000148	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—breast cancer	2e-05	0.000148	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—breast cancer	1.99e-05	0.000147	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—breast cancer	1.89e-05	0.000139	CcSEcCtD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	1.92e-06	1.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA2—breast cancer	1.91e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—breast cancer	1.91e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTR—breast cancer	1.9e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CPT1A—breast cancer	1.9e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCG2—breast cancer	1.9e-06	1.53e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX2—breast cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA2—breast cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NQO1—breast cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A1—breast cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—FASN—breast cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—breast cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SULT1A1—breast cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX4—breast cancer	1.87e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—breast cancer	1.86e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BCHE—breast cancer	1.86e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HBA1—breast cancer	1.86e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—FASN—breast cancer	1.85e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BCHE—breast cancer	1.85e-06	1.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A5—breast cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP3A4—breast cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—breast cancer	1.83e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A5—breast cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA1—breast cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—IDH1—breast cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—breast cancer	1.81e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ACHE—breast cancer	1.81e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PLA2G4A—breast cancer	1.81e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—breast cancer	1.81e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NCOR1—breast cancer	1.81e-06	1.46e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1B1—breast cancer	1.81e-06	1.45e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—breast cancer	1.8e-06	1.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAT2—breast cancer	1.8e-06	1.45e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	1.8e-06	1.45e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—breast cancer	1.79e-06	1.44e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A1—breast cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NQO1—breast cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—breast cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HSP90AA1—breast cancer	1.77e-06	1.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NQO1—breast cancer	1.76e-06	1.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A1—breast cancer	1.76e-06	1.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP3A4—breast cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—breast cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.73e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOA1—breast cancer	1.72e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP3A4—breast cancer	1.72e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP17A1—breast cancer	1.71e-06	1.38e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.71e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1B1—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ERCC2—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP19A1—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—STK11—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO1—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS1—breast cancer	1.7e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.69e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1B1—breast cancer	1.69e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.67e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	1.67e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2D6—breast cancer	1.66e-06	1.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HSP90AA1—breast cancer	1.66e-06	1.33e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA2—breast cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOA1—breast cancer	1.63e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA1—breast cancer	1.61e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—STK11—breast cancer	1.6e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP19A1—breast cancer	1.6e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—breast cancer	1.6e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP19A1—breast cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—STK11—breast cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—breast cancer	1.59e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—FASN—breast cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MED12—breast cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—DPYD—breast cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—COMT—breast cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BCHE—breast cancer	1.58e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—breast cancer	1.57e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—breast cancer	1.57e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A5—breast cancer	1.56e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDOA—breast cancer	1.56e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—breast cancer	1.55e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—breast cancer	1.55e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ITPR1—breast cancer	1.55e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA3—breast cancer	1.51e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NQO1—breast cancer	1.51e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A1—breast cancer	1.51e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A2—breast cancer	1.5e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—breast cancer	1.5e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—COMT—breast cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—breast cancer	1.48e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—COMT—breast cancer	1.48e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAV1—breast cancer	1.48e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.47e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG2—breast cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CPT1A—breast cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTR—breast cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—breast cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP3A4—breast cancer	1.47e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—breast cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—breast cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.46e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ITPR1—breast cancer	1.46e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—breast cancer	1.45e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ITPR1—breast cancer	1.45e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—breast cancer	1.45e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PLA2G4A—breast cancer	1.45e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOR1—breast cancer	1.45e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1B1—breast cancer	1.44e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—breast cancer	1.44e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HBA1—breast cancer	1.43e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.42e-06	1.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.41e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—breast cancer	1.4e-06	1.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—breast cancer	1.4e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACHE—breast cancer	1.4e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—breast cancer	1.39e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—breast cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—breast cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—breast cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA1—breast cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—breast cancer	1.37e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—breast cancer	1.37e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—breast cancer	1.37e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOR1—breast cancer	1.36e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.36e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—breast cancer	1.36e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ERCC2—breast cancer	1.36e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—STK11—breast cancer	1.36e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP19A1—breast cancer	1.36e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PLA2G4A—breast cancer	1.35e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—breast cancer	1.35e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOR1—breast cancer	1.35e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—breast cancer	1.34e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—breast cancer	1.34e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP17A1—breast cancer	1.32e-06	1.06e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO1—breast cancer	1.31e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS1—breast cancer	1.31e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—breast cancer	1.3e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—breast cancer	1.29e-06	1.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—breast cancer	1.29e-06	1.04e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2D6—breast cancer	1.28e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ERCC2—breast cancer	1.28e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—breast cancer	1.28e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—breast cancer	1.28e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ERCC2—breast cancer	1.27e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—COMT—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA2—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—breast cancer	1.26e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—breast cancer	1.24e-06	9.96e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ITPR1—breast cancer	1.24e-06	9.94e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FASN—breast cancer	1.22e-06	9.84e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BCHE—breast cancer	1.22e-06	9.79e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—breast cancer	1.2e-06	9.68e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A5—breast cancer	1.2e-06	9.67e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—breast cancer	1.19e-06	9.6e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—breast cancer	1.19e-06	9.6e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—breast cancer	1.19e-06	9.56e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—breast cancer	1.18e-06	9.5e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAV1—breast cancer	1.18e-06	9.48e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—breast cancer	1.17e-06	9.39e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—breast cancer	1.17e-06	9.38e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NQO1—breast cancer	1.16e-06	9.34e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A1—breast cancer	1.16e-06	9.34e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOR1—breast cancer	1.15e-06	9.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.15e-06	9.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—breast cancer	1.15e-06	9.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—breast cancer	1.12e-06	8.97e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1B1—breast cancer	1.11e-06	8.96e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAV1—breast cancer	1.11e-06	8.93e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—breast cancer	1.11e-06	8.89e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAV1—breast cancer	1.1e-06	8.85e-06	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—breast cancer	1.1e-06	8.83e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—breast cancer	1.09e-06	8.8e-06	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—breast cancer	1.09e-06	8.79e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.09e-06	8.78e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ERCC2—breast cancer	1.08e-06	8.72e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—breast cancer	1.07e-06	8.63e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA1—breast cancer	1.06e-06	8.55e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.05e-06	8.46e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—STK11—breast cancer	1.05e-06	8.42e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP19A1—breast cancer	1.05e-06	8.42e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—breast cancer	1.03e-06	8.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—breast cancer	1.02e-06	8.2e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—breast cancer	1.02e-06	8.2e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—breast cancer	1.01e-06	8.13e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—breast cancer	1e-06	8.06e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—COMT—breast cancer	9.74e-07	7.83e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—breast cancer	9.69e-07	7.79e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—breast cancer	9.56e-07	7.69e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ITPR1—breast cancer	9.54e-07	7.67e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—breast cancer	9.44e-07	7.59e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAV1—breast cancer	9.41e-07	7.56e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—breast cancer	9.31e-07	7.49e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—breast cancer	9.17e-07	7.38e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—breast cancer	9.01e-07	7.24e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	8.99e-07	7.23e-06	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—breast cancer	8.93e-07	7.18e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—breast cancer	8.91e-07	7.16e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOR1—breast cancer	8.91e-07	7.16e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—breast cancer	8.91e-07	7.16e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLA2G4A—breast cancer	8.91e-07	7.16e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—breast cancer	8.9e-07	7.15e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—breast cancer	8.89e-07	7.15e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—breast cancer	8.81e-07	7.09e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—breast cancer	8.78e-07	7.06e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—breast cancer	8.7e-07	7e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—breast cancer	8.57e-07	6.89e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—breast cancer	8.53e-07	6.86e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—breast cancer	8.44e-07	6.79e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—breast cancer	8.42e-07	6.77e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—breast cancer	8.4e-07	6.75e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ERCC2—breast cancer	8.37e-07	6.73e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—breast cancer	8.32e-07	6.69e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—breast cancer	8.22e-07	6.61e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—breast cancer	8.15e-07	6.55e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—breast cancer	7.87e-07	6.33e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—breast cancer	7.75e-07	6.23e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—breast cancer	7.68e-07	6.18e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—breast cancer	7.68e-07	6.17e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—breast cancer	7.61e-07	6.12e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—breast cancer	7.53e-07	6.06e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—breast cancer	7.44e-07	5.98e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAV1—breast cancer	7.26e-07	5.84e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—breast cancer	7.11e-07	5.72e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—breast cancer	7.11e-07	5.71e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—breast cancer	6.88e-07	5.53e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—breast cancer	6.7e-07	5.39e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—breast cancer	6.64e-07	5.34e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—breast cancer	6.61e-07	5.32e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—breast cancer	6.57e-07	5.28e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—breast cancer	6.51e-07	5.23e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—breast cancer	6.28e-07	5.05e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—breast cancer	5.81e-07	4.67e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—breast cancer	5.74e-07	4.61e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—breast cancer	5.67e-07	4.56e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—breast cancer	5.49e-07	4.41e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—breast cancer	5.13e-07	4.12e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—breast cancer	5.07e-07	4.07e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—breast cancer	5.02e-07	4.04e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—breast cancer	5.01e-07	4.03e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—breast cancer	4.72e-07	3.8e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—breast cancer	4.68e-07	3.77e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—breast cancer	4.38e-07	3.52e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—breast cancer	4.1e-07	3.29e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—breast cancer	4e-07	3.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—breast cancer	3.86e-07	3.1e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—breast cancer	3.83e-07	3.08e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—breast cancer	3.27e-07	2.63e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—breast cancer	3.09e-07	2.48e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—breast cancer	2.52e-07	2.03e-06	CbGpPWpGaD
